The 3 Most Important Things to Know About Pfizer's Q4 Earnings Results
Everyone who follows Pfizer (NYSE: PFE) expected that 2019 would be a challenging year for the big drugmaker. And it was. The company's blockbuster nerve-pain drug Lyrica faced generic competition, with sales quickly plummeting. Pfizer's share price fell 10% last year, while the S&P 500 index soared 29%.
Pfizer announced its fourth-quarter results before the market opened on Tuesday. Here are the three most important things to know about the company's Q4 update.
Image source: Getty Images.
Source Fool.com
